Renaissance Technologies
CNSP icon

Renaissance Technologies’s CNS Pharmaceuticals CNSP Stock Holding History

Renaissance Technologies’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Hold
0
– -$14K – 3756
2023
Q4 		– Hold
0
– – – 3616
2023
Q2 		– Sell
-1
Closed -$27K – 3962
2023
Q1 		$27K Buy
+1
New +$56K ﹤0.01% 3772
2022
Q4 		– Hold
0
– -$10K – 4144
2022
Q3 		– Hold
0
– – – 3947
2022
Q2 		– Sell
-1
Closed -$173K – 4263
2022
Q1 		$173K Buy
+1
New +$422K ﹤0.01% 3686
2021
Q4 		– Hold
0
– – – 3674
2021
Q3 		– Hold
0
– -$847K – 3523
2021
Q2 		– Sell
-1
Closed -$1.8M – 2750
2021
Q1 		$1.73M Buy
+1
New +$2.27M ﹤0.01% 2314

Other funds holding CNSP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Renaissance Technologies's CNSP Position: Q1 2024 in Review

Renaissance Technologies held its CNS Pharmaceuticals (CNSP) position steady in Q1 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3756.

Renaissance Technologies first reported a position in CNSP in Q1 2021 and has held it in 3 quarters since. The position peaked at $1.73M in Q1 2021. 12 funds tracked by Wall St. Rank hold CNSP as of Q1 2024.

  • Renaissance Technologies held 0 shares of CNS Pharmaceuticals worth $0 as of Q1 2024.
  • Renaissance Technologies left its CNS Pharmaceuticals share count unchanged in Q1 2024.
  • CNS Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2024, its #3756 holding.
  • Renaissance Technologies first reported a position in CNS Pharmaceuticals in Q1 2021 and has held it in 3 quarters since.
  • Renaissance Technologies's CNS Pharmaceuticals position peaked at $1.73M in Q1 2021.
  • 12 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q1 2024.

Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.